Drugs facing NCE-1 in 2030
Drugs becoming eligible for first Paragraph IV ANDA filing in 2030
1. Adquey patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46792 | ACROTECH | NA |
Mar, 2028
(1 year, 6 months from now) | |
| US10588893 | ACROTECH | Ointment Containing An Oxazole Compound |
Dec, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2031 |
Drugs and Companies using DIFAMILAST ingredient
NCE-1 date: 12 February, 2030
Market Authorisation Date: 12 February, 2026
Treatment: Method of treating atopic dermatitis
Dosage: OINTMENT
More Information on Dosage
ADQUEY family patents
2. Ambelvist patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10722601 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US10137209 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US12478696 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| US11491245 | BAYER | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging |
May, 2036
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12303573 | BAYER | Formulation Of Contrast Media And Process Of Preparation Thereof |
Nov, 2039
(13 years from now) | |
| US11944690 | BAYER | Formulation Of Contrast Media And Process Of Preparation Thereof |
May, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 12, 2031 |
Drugs and Companies using GADOQUATRANE ingredient
NCE-1 date: 12 June, 2030
Market Authorisation Date: 12 June, 2026
Treatment: Method of magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax,...
Dosage: SOLUTION
More Information on Dosage
AMBELVIST family patents
3. Baxfendy patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9353081 | ASTRAZENECA | Bicyclic Dihydroquinoline-2-One Derivatives |
Feb, 2033
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2031 |
Drugs and Companies using BAXDROSTAT ingredient
NCE-1 date: 15 May, 2030
Market Authorisation Date: 15 May, 2026
Treatment: NA
Dosage: TABLET
More Information on Dosage
BAXFENDY family patents
4. Beqalzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11420968 | BEONE MEDICINES | Bcl-2 Inhibitors |
Apr, 2039
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2031 |
Drugs and Companies using SONROTOCLAX ingredient
NCE-1 date: 13 May, 2030
Market Authorisation Date: 13 May, 2026
Treatment: NA
Dosage: TABLET
More Information on Dosage
BEQALZI family patents
5. Bysanti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570453 | VANDA | Method Of Predicting A Predisposition To Qt Prolongation |
Mar, 2028
(1 year, 6 months from now) | |
| US9157121 | VANDA | Method of treatment based on polymorphisms of the KCNQ1 gene |
Apr, 2030
(3 years from now) | |
| US10563259 | VANDA | Method Of Treatment Based On Polymorphisms Of The Kcnq1 Gene |
Jul, 2030
(3 years from now) | |
| US12606869 | VANDA | Methods For The Administration Of Iloperidone |
Sep, 2030
(4 years from now) | |
| US8999638 | VANDA | Method of treatment based on polymorphisms of the KCNQ1 gene |
Oct, 2030
(4 years from now) | |
| US9074255 | VANDA | Method of predicting a predisposition to QT prolongation |
Dec, 2030
(4 years from now) | |
| US9072742 | VANDA | Method of predicting a predisposition to QT prolongation |
Jan, 2031
(4 years from now) | |
| US9074256 | VANDA | Method of predicting a predisposition to QT prolongation |
Feb, 2031
(4 years from now) | |
| US9074254 | VANDA | Method of predicting a predisposition to QT prolongation |
Dec, 2031
(5 years from now) | |
| US12478619 | VANDA | Method Of Treatment With Milsaperidone |
May, 2044
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 20, 2031 |
Drugs and Companies using MILSAPERIDONE ingredient
NCE-1 date: 20 February, 2030
Market Authorisation Date: 20 February, 2026
Treatment: Method for acute treatment of manic or mixed episodes associated with bipolar i disorder in adults by administering milsaperidone to a patient by lowering the dose after determining that the patient h...
Dosage: TABLET
More Information on Dosage
BYSANTI family patents
6. Foundayo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50455 | ELI LILLY | NA |
Sep, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 01, 2031 |
Drugs and Companies using ORFORGLIPRON CALCIUM ingredient
NCE-1 date: 01 April, 2030
Market Authorisation Date: 01 April, 2026
Treatment: Treatment to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition by administering an effective am...
Dosage: TABLET
More Information on Dosage
FOUNDAYO family patents
7. Icotyde patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12552836 | JANSSEN | Peptide Inhibitors Of Interleukin-23 Receptor And Their Use To Treat Inflammatory Diseases |
Jul, 2039
(12 years from now) | |
| US11845808 | JANSSEN | Peptide Inhibitors Of Interleukin-23 Receptor And Their Use To Treat Inflammatory Diseases |
Jan, 2041
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11939361 | JANSSEN | Compositions Of Peptide Inhibitors Of Interleukin-23 Receptor |
Nov, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 17, 2031 |
Drugs and Companies using ICOTROKINRA HYDROCHLORIDE ingredient
NCE-1 date: 17 March, 2030
Market Authorisation Date: 17 March, 2026
Treatment: Treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy
Dosage: TABLET
More Information on Dosage
ICOTYDE family patents
8. Idvynso patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7339053 | MERCK | 4'-C-Substituted-2-Haloadenosine Derivative |
May, 2027
(8 months from now) | |
| US8486975 | MERCK | Non-nucleoside reverse transcriptase inhibitors |
Aug, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 20, 2031 |
Drugs and Companies using DORAVIRINE; ISLATRAVIR ingredient
NCE-1 date: 20 April, 2030
Market Authorisation Date: 20 April, 2026
Treatment: Use of a complete two-drug regimen for the treatment of hiv-1 infection in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral reg...
Dosage: TABLET
More Information on Dosage
IDVYNSO family patents
9. Lifyorli (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8859774 | CORCEPT | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(6 years from now) | |
| US11576907 | CORCEPT | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9273047 | CORCEPT | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(6 years from now) | |
| US10456392 | CORCEPT | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(6 years from now) | |
| US12514849 | CORCEPT | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound |
Dec, 2039
(13 years from now) | |
| US11925626 | CORCEPT | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound |
Dec, 2039
(13 years from now) | |
| US11464764 | CORCEPT | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound |
Apr, 2040
(13 years from now) | |
| US11285145 | CORCEPT | Concomitant Administration Of Glucocorticoid Receptor Modulator Relacorilant And Paclitaxel, A Dual Substrate Of Cyp2C8 And Cyp3A4 |
May, 2041
(14 years from now) | |
| US12589094 | CORCEPT | Concomitant Administration Of Glucocorticoid Receptor Modulator Relacorilant And Paclitaxel, A Dual Substrate Of Cyp2C8 And Cyp3A4 |
May, 2041
(14 years from now) | |
| US12152028 | CORCEPT | Methods Of Preparing Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
Dec, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2031 |
Drugs and Companies using RELACORILANT ingredient
NCE-1 date: 25 March, 2030
Market Authorisation Date: 25 March, 2026
Treatment: Treatment of platinum-resistant primary peritoneal cancer with lifyorli in combination with nab-paclitaxel, in adults who have received one to three prior systemic treatment regimens, at least one of ...
Dosage: CAPSULE
More Information on Dosage
LIFYORLI (COPACKAGED) family patents
10. Lipfendra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11427616 | MERCK | Pcsk9 Antagonist Compounds |
Feb, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 15, 2031 |
Drugs and Companies using ENLICITIDE DECANOATE ingredient
NCE-1 date: 15 July, 2030
Market Authorisation Date: 15 July, 2026
Treatment: Reduction of ldl-c in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (hefh)
Dosage: TABLET
More Information on Dosage
LIPFENDRA family patents